A previously reported, industry-sponsored phase 3 trial showed improvements in progression-free survival, objective response, and a non-significant trend toward increased overall survival with panitumumab-FOLFIRI vs FOLFIRI alone for second-line wild-type KRAS metastatic colorectal cancer. Go Back
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.